Benchmark Reports
Independent benchmarking and regulatory insights supporting quality, compliance and operational excellence.
UPCOMINGClusterARREPORT
European Cannabis GMP Benchmark Report 2026–2027
ClusterAR's inaugural independent European assessment of GMP maturity, quality systems and regulatory compliance across licensed medical cannabis manufacturers.
Independent Research
Anonymised Data
Evidence-Based
European Scope
STATUS
Research in Progress
EXPECTED PUBLICATION
Q2 2027
REGULATORY AUTHORITIES
View All Authorities

EMA
European Medicines Agency
- Guidelines
- CHMP Opinions
- GMP News
- Scientific Publications

U.S. Food & Drug Administration
- Warning Letters
- GMP Guidance
- Cannabis Research
- Drug Approvals

MHRA
United Kingdom
- Regulatory Updates
- GMP Guidance
- Safety Alerts
- Medicines Information

Health Canada
Canada
- Cannabis Regulations
- Licensing
- Guidance Documents
- Safety Communications
LATEST REGULATORY INTELLIGENCE
View All Updates →
EMA
New guideline on quality of herbal medicinal products
May 14, 2024
FDA
FDA issues 4 warning letters for GMP deficiencies
May 10, 2024
INFARMED
Circular Informativa N.º 058/CD/2024
May 09, 2024
MHRA
GMP inspection findings published
May 07, 2024
Health Canada
Cannabis licensing updates
May 06, 2024
TGA
Updates to GMP guidance for manufacturers
May 03, 2024
BENCHMARK CATEGORIES
Compliance
Systems
& Records
& Qualification
Management
& Processing
& Operations
Testing
STAY UPDATED
Recieve the latest regulatory intelligence and updates on our upcoming benchmark reports.
We respect your privacy. Unsubscribe at any time
HAVE QUESTIONS?
Contact our research team for more information about our benchmark reports.
Building evidence. Driving excellence. Shaping the future of cannabis.it.
All content aggregated from official sources. Last updated: May 14, 2024.